Surgical Complications After Neoadjuvant Treatment for Borderline Resectable Pancreatic Cancer: From Benchmarks to Randomized Clinical Trials
Author:
Publisher
Springer Science and Business Media LLC
Link
https://link.springer.com/content/pdf/10.1245/s10434-024-16134-7.pdf
Reference15 articles.
1. PancreasGroup.org Collaborative. Pancreatic surgery outcomes: multicentre prospective snapshot study in 67 countries. Br J Surg. 2024;111(1):znad330.
2. van Dam JL, Janssen QP, Besselink MG, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials. Eur J Cancer. 2022;160:140–9.
3. Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial. JAMA Oncol. 2022;8(9):1263–70.
4. Snyder RA, Zemla TJ, Shi Q, et al. Postoperative adverse events following neoadjuvant therapy and surgery for borderline resectable pancreatic cancer in a phase 2 clinical trial (Alliance A021501). Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15670-6.
5. Raptis DA, Sánchez-Velázquez P, Machairas N, et al. Defining benchmark outcomes for pancreatoduodenectomy with portomesenteric venous resection. Ann Surg. 2020;272(5):731–7.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3